April 26 (Reuters) - Anika Therapeutics Inc:
* Comments on patent litigation
* Says intends to continue to vigorously defend the lawsuits and the monovisc
product franchise
* Genzyme corporation has amended its original patent infringement lawsuit with
respect to monovisc
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Comments on patent litigation
* Says intends to continue to vigorously defend the lawsuits and the monovisc
product franchise
* Genzyme corporation has amended its original patent infringement lawsuit with
respect to monovisc
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.